Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

16
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

726
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
726
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

27
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
27
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

19
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
19
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

223
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
223
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

18
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
18

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Contemporary Clinical Practices in Korean Patients With Coronary Chronic Total Occlusion: Results From the K-CTO Nationwide Retrospective Registry.

Korean circulation journal·2026
Same author

Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-Analysis.

JAMA cardiology·2026
Same author

Optical coherence tomography-guided PCI in left anterior descending versus non-left anterior descending lesions: a prespecified substudy of the OCCUPI trial.

The international journal of cardiovascular imaging·2026
Same author

Sex Differences in Prognostic Implications of CYP2C19 Genotype After Drug-Eluting Stent Implantation.

Journal of the American Heart Association·2026
Same author

OCT-Guided PCI According to Lesion Length and Vessel Diameter: Post Hoc Analysis of OCCUPI Trial.

JACC. Asia·2026
Same author

Optimal antiplatelet strategy in patients with advanced chronic kidney disease undergoing drug-eluting stent implantation: Design and rationale of the randomized ADAPT-CKD trial.

American heart journal·2026

Video Experimental Relacionado

Updated: Aug 8, 2025

Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training
07:40

Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training

Published on: October 10, 2019

7.4K

Tratamiento al objetivo o estatina de alta intensidad en pacientes con enfermedad arterial coronaria: un ensayo

Sung-Jin Hong1, Yong-Joon Lee1, Seung-Jun Lee1

  • 1Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.

JAMA
|March 6, 2023
PubMed
Resumen

Una estrategia de tratamiento de colesterol de lipoproteína de baja densidad (LDL-C) no fue inferior al tratamiento con estatinas de alta intensidad en pacientes con enfermedad arterial coronaria. Este enfoque asegura resultados clínicos comparables mientras permite la dosificación personalizada de estatinas.

Más Videos Relacionados

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.3K

Videos de Experimentos Relacionados

Last Updated: Aug 8, 2025

Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training
07:40

Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training

Published on: October 10, 2019

7.4K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.3K

Área de la Ciencia:

  • Medicina cardiovascular
  • Ensayos clínicos
  • Farmacología

Sus antecedentes:

  • Las directrices actuales ofrecen diferentes recomendaciones de intensidad de estatinas para la enfermedad arterial coronaria (CAD).
  • Las comparaciones directas de las estrategias de tratamiento-objetivo frente a las de estatinas de alta intensidad son limitadas en pacientes con EAC.

Objetivo del estudio:

  • Evaluar si una estrategia de tratamiento al objetivo no es inferior a las estatinas de alta intensidad para los resultados clínicos a largo plazo en CAD.
  • Comparar la eficacia y la seguridad de las metas individualizadas de LDL-C frente a la intensidad máxima de estatinas.

Principales métodos:

  • Un ensayo aleatorizado, multicéntrico, de no inferioridad que involucra a pacientes con enfermedad arterial coronaria diagnosticada.
  • A los pacientes se les asignó un objetivo de colesterol LDL de 50-70 mg/ dl o una terapia con estatinas de alta intensidad (rosuvastatina 20 mg o atorvastatina 40 mg).
  • El criterio de valoración primario fue una combinación de 3 años de muerte, infarto de miocardio, accidente cerebrovascular o revascularización coronaria.

Principales resultados:

  • La estrategia de tratamiento-objetivo (C-LDL promedio: 69,1 mg/ dl) no fue inferior a la terapia con estatinas de alta intensidad (C-LDL promedio: 68,4 mg/ dl).
  • El criterio de valoración primario se produjo en el 8,1% del grupo de tratamiento al objetivo frente al 8,7% del grupo de alta intensidad (P < 0,001 para la no inferioridad).
  • Esto indica una eficacia comparable en la prevención de eventos cardiovasculares adversos mayores durante 3 años.

Conclusiones:

  • Una estrategia de tratamiento dirigido al colesterol LDL es una alternativa adecuada al tratamiento con estatinas de alta intensidad en pacientes con EAC.
  • Este enfoque permite un tratamiento personalizado, adaptado a las respuestas individuales a las estatinas.
  • Los hallazgos apoyan la terapia personalizada con estatinas para el tratamiento de la enfermedad arterial coronaria.